Disease · MONDO_0004880

bowel dysfunction

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. bowel dysfunction. Diseases, record MONDO_0004880. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004880

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: bowel dysfunction; Open Targets
Open Targets ID: MONDO_0004880; Open Targets
Other names: disease of lower digestive tract, lower digestive tract disease; Open Targets
Disease Ontology: DOID:9779; Disease Ontology
Highest stage of its drugs: Phase 3, for 3 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LUBIPROSTONE	CHEMBL1201134	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
ALVIMOPAN	CHEMBL270190	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
RIFAXIMIN	CHEMBL1617	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLNALTREXONE BROMIDE	CHEMBL1201770	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets13

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
OPRM1	Mu-type opioid receptor	2	Mu opioid receptor antagonist	Phase 3	https://conductscience.org/library/genes/4988	Drugs and targets
CLCN2	Chloride channel protein 2	1	Chloride channel protein 2 opener	Phase 3	https://conductscience.org/library/genes/1181	Drugs and targets
SCN10A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6329	Drugs and targets
SCN5A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6331	Drugs and targets
SCN7A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6332	Drugs and targets

1 to 10 of 13

See all 13 targets

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00620061	Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone	Phase 3	439	2019-12-30	Opioid-Induced Bowel Dysfunction	LUBIPROSTONE	Its record names the disease	ClinicalTrials.gov
NCT01298219	Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)	Phase 3	439	2019-12-24	Opioid-induced Bowel Dysfunction	LUBIPROSTONE	Its record names the disease	ClinicalTrials.gov
NCT00597428	Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone	Phase 3	437	2015-12-07	Opioid-Induced Bowel Dysfunction	LUBIPROSTONE	Its record names the disease	ClinicalTrials.gov
NCT01345175	Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer	Phase 3	69	2024-05-14	Rectal Cancer	RIFAXIMIN	Its record names the disease	ClinicalTrials.gov
NCT00241722	Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain	Phase 3	805		Bowel Dysfunction, Constipation	ALVIMOPAN	Its record names the disease	ClinicalTrials.gov
NCT00259922	Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain	Phase 3	485		Bowel Dysfunction, Constipation	ALVIMOPAN	Its record names the disease	ClinicalTrials.gov
NCT00366431	Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain	Phase 2	420		Constipation	METHYLNALTREXONE BROMIDE	Its record names the disease	ClinicalTrials.gov
NCT01155440	Bowel Function After Laparoscopic Colon Surgery: Effect of IV Lidocaine	Phase 2	60		Colon Cancer, Inflammatory Bowel Diseases, Diverticulitis	LIDOCAINE	Its record names the disease	ClinicalTrials.gov
NCT04991688	A Prospective Pilot Study to Assess the Efficacy of BOTOX-A in Patients With Low Anterior Resection Syndrome (LARS>20) and Refractory Medical Treatment After Rectal Resection	Phase 2	11		Low Anterior Resection Syndrome (LARS>20), Refractory Medical Treatment After Rectal Resection	BOTULINUM TOXIN TYPE A	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Lubiprostone vs Placebo: Number of Participants Classified as Treatment Responders Within 12 Weeks	59 of 219	41 of 220	439	NCT01298219	Trial comparisons
Lubiprostone vs Placebo: deaths from any cause	1 of 219	0 of 220	439	NCT01298219	Trial comparisons
Lubiprostone vs Placebo: serious adverse events	7 of 219	6 of 220	439	NCT01298219	Trial comparisons
Lubiprostone vs Placebo: serious adverse events	7 of 223	7 of 214	437	NCT00597428	Trial comparisons
Lubiprostone vs Placebo: Responder Rate	108 of 223	100 of 212	435	NCT00597428	Trial comparisons
Arm 1: Experimental: Pts Receiving Rifaximin vs Arm 2: Placebo Comparator: Pts Receiving Placebo: deaths from any cause	0 of 36	0 of 33	69	NCT01345175	Trial comparisons
Arm 1: Experimental: Pts Receiving Rifaximin vs Arm 2: Placebo Comparator: Pts Receiving Placebo: serious adverse events	0 of 36	1 of 33	69	NCT01345175	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21292168	RESULT	1	PubMed
21519309	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004880

GET https://conductscience.org/api/diseases/v1/MONDO_0004880/drugs

API reference For AI assistants